Stifel Nicolaus Raises Inogen (NASDAQ:INGN) Price Target to $7.00

Inogen (NASDAQ:INGN) had its price objective hoisted by Stifel Nicolaus from $6.00 to $7.00 in a report published on Wednesday, Benzinga reports. They currently have a hold rating on the medical technology company’s stock.

A number of other research firms also recently commented on INGN. William Blair upgraded Inogen from a market perform rating to an outperform rating in a research report on Thursday, February 15th. Needham & Company LLC reiterated a hold rating on shares of Inogen in a research report on Wednesday. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Inogen has a consensus rating of Hold and a consensus price target of $7.00.

Inogen Stock Up 2.8 %

NASDAQ:INGN traded up $0.23 during mid-day trading on Wednesday, hitting $8.47. 97,325 shares of the company traded hands, compared to its average volume of 524,943. The stock’s fifty day moving average price is $7.11 and its 200-day moving average price is $6.51. Inogen has a one year low of $4.13 and a one year high of $11.98. The firm has a market cap of $199.44 million, a price-to-earnings ratio of -1.87 and a beta of 1.10.

Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, May 7th. The medical technology company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.14. The firm had revenue of $78.03 million during the quarter, compared to analyst estimates of $73.67 million. Inogen had a negative return on equity of 38.98% and a negative net margin of 32.46%. The business’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.63) earnings per share. Equities analysts predict that Inogen will post -2.56 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. increased its holdings in shares of Inogen by 347.2% in the 4th quarter. Federated Hermes Inc. now owns 265,485 shares of the medical technology company’s stock valued at $1,458,000 after acquiring an additional 206,125 shares during the period. Acadian Asset Management LLC grew its position in shares of Inogen by 195.6% in the 3rd quarter. Acadian Asset Management LLC now owns 389,792 shares of the medical technology company’s stock worth $2,033,000 after buying an additional 257,940 shares during the last quarter. Glenmede Trust Co. NA raised its stake in shares of Inogen by 39.8% during the 3rd quarter. Glenmede Trust Co. NA now owns 39,670 shares of the medical technology company’s stock worth $207,000 after acquiring an additional 11,285 shares in the last quarter. Meros Investment Management LP lifted its position in Inogen by 14.9% during the third quarter. Meros Investment Management LP now owns 589,604 shares of the medical technology company’s stock valued at $3,078,000 after acquiring an additional 76,294 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in Inogen by 73.9% during the third quarter. Assenagon Asset Management S.A. now owns 225,730 shares of the medical technology company’s stock valued at $1,178,000 after acquiring an additional 95,913 shares during the last quarter. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.